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Abstract: Non-coding RNAs (ncRNAs) are involved in the regulation of cell metabolism and
neoplastic transformation. Recent studies have tried to clarify the significance of these information
carriers in the genesis and progression of various cancers and their use as biomarkers for the disease;
possible targets for the inhibition of growth and invasion by the neoplastic cells have been suggested.
The significance of ncRNAs in lung cancer, bladder cancer, kidney cancer, and melanoma has been
amply investigated with important results. Recently, the role of long non-coding RNAs (lncRNAs)
has also been included in cancer studies. Studies on the relation between endometrial cancer (EC)
and ncRNAs, such as small ncRNAs or micro RNAs (miRNAs), transfer RNAs (tRNAs), ribosomal
RNAs (rRNAs), antisense RNAs (asRNAs), small nuclear RNAs (snRNAs), Piwi-interacting RNAs
(piRNAs), small nucleolar RNAs (snoRNAs), competing endogenous RNAs (ceRNAs), lncRNAs, and
long intergenic ncRNAs (lincRNAs) have been published. The recent literature produced in the last
three years was extracted from PubMed by two independent readers, which was then selected for the
possible relation between ncRNAs, oncogenesis in general, and EC in particular.
Keywords: endometrial cancer; epigenetics; non-coding RNA (ncRNA); long non-coding RNA
(lncRNA); small non-coding RNA (small ncRNA)
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1. Introduction
The analysis of non-coding RNA (ncRNAs) expression in endometrial cancers (EC) might be
of importance in understanding the neoplastic transformation of the endometrium. These RNA
transcripts are possible biomarkers of early neoplastic transformation, but their significance might be
even greater.
Approximately only 2% of the genome in humans has protein encoding functions, so most of
the human genome is not translated into proteins. It has been called genomic dark matter, because no
specific function has been described for it [1]. However, many information-carrying genes have been
demonstrated to have significant regulatory functions, even if they remain untranslated. The ncRNAs
include transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), antisense RNAs (asRNA), micro RNAs
(miRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), competing endogenous
RNAs (ceRNAs) and piwi-interacting RNAs (piRNAs).
Recently, an additional group of ncRNAs has been discovered: they are called long-ncRNAs
(lncRNAs), as they are over 200 nucleotides in length, in contrast to other ncRNAs, which are
usually shorter [2,3]. lncRNAs are less comparable between species; protein-coding genes tend
to be homologous between mammals [4]. Four main mechanisms are involved in their expression
and they are sometimes defined as archetypes: signaling, decoying, scaffolding and guidance [5,6].
lncRNAs seem to have an importance in physiological regulation, and their dysfunction has been
implicated in cardiovascular and neurodegenerative diseases as well as in cancers [7,8]. lncRNAs
seem to be important modulators in biological mechanisms and significant cofactors of tumorogenesis.
lncRNA gene polymorphisms have been linked to cancer risk [9]. Systematic reviews on the association
between lncRNA single-nucleotide polymorphisms (SNPs) and the overall risk of developing a cancer
are starting to appear in the literature. A total of 17 SNPs in four common lncRNA genes have
already been described by Zhi et al. in a meta-analysis [9]. However, the involvement of lncRNAs
in endometrioid endometrial adenocarcinoma (EEC) remains to be fully addressed. Indeed, RNAs
are expressed in different ways in the normal, hyperplastic and dysplastic endometrium [6]; hence,
interference in RNA expression could actually lead to the clinical control of neoplastic transformation
and disease progression. We offer an overview of the current knowledge of the relationship between
ncRNAs and endometrial adenocarcinoma (EC) that shows promise in the diagnosis and treatment of
this condition.
2. Endometrial Cancer: Overview
With over 189,000 new cases and about 45,000 deaths worldwide per year, EC is the second most
common gynecologic tumor [10,11]. About 54,870 cases were diagnosed in the United States in 2015,
with about 10,170 deaths [12]. A relevant role in EC etiology is played by social and cultural variables,
as well as socio-economic disparities among ethnic groups in some countries, because of the differential
availability of medical treatments.
Two different types of EC can be identified using pathological and demographic parameters: Type
I EC, also known as EEC, derives from the hyperplastic endometrium due to high endogenous estrogen
production. Thus, it affects women both prior to and after menopause, and shows an average lower
age of incidence (40–50 years). These tumors are usually well-differentiated, with average recurrence
rates of 20%. Type II EC is post-menopausal, so the average age of incidence is about 60 years; no
precise relationship with host estrogen production has been demonstrated [13].
About 80% of type I tumors show downregulation or mutations of the phosphatase
and tensin (PTEN) gene [14,15], leading to an enhanced activity of the phosphatidylinositide
3-kinase–Akt–mammalian target of Rapamycin (PI3K/Akt/mTOR) signaling pathway. Furthermore,
the activity of the K-ras oncogene or of the fibroblast growth factor receptor (FGFR) seems to lead to
high levels of mitogen-activated protein kinases (MAPKs), with added phosphorylation of the estrogen
receptor (ER) in a β-catenin-dependent manner [16]. This leads to unwarranted transcriptional effects
as well as ER activation with a deregulation of cellular proliferation and consequent tumorigenesis [17].
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Type II EC, or non-endometrioid endometrial carcinoma (NEEC), is not related to circulating
estrogen levels. These tumors originate from atrophic endometrial tissue in post-menopause [18].
Type II EC can be undifferentiated or show histological features consistent with serous, endometrioid,
or clear-cell differentiation. They are usually diagnosed at an advanced stage, with distant metastases
already present, and their prognosis is poor even with advanced treatment [19]. More than half
of Type II EC recurs within five years of surgery [13]. At proteomics, NEEC tissue samples show
a high expression of mutant tumor protein 53 (TP53) and tumor suppressor protein 16 (P16), usually
considered non-functional proteins [6,20].
Because protein expression in EC seems altered, protein coding regulation anomalies typically
associated with RNA inhibitory activity have often been suggested. The ncRNAs show promise as
diagnostic biomarkers, indicators of progression, lymph node status, therapy response, and even as
targets for tumorigenesis and progression mechanisms interference with considerable therapeutic
potential. ncRNA significance has been investigated in relation to endometrial cancer, providing
preliminary results.
Long Non-Coding RNAs: General Introduction
lncRNAs cover a large part of the non-coding information of the human DNA, which represents
more than 90% of the whole genome. They constitute a wide and complex group of molecules with
more than 200 nucleotides, usually lack an open reading frame, and in various ways are involved in
the pathophysiology of cancer [2,3,5]. Their roles in the regulation of gene expression, imprinting,
transcription, and post-translational processing have been documented in several types of cancer.
Thousands of long intergenic ncRNAs (lincRNAs) have been identified in various mammals in genome
sequencing studies. Some of these RNAs have been conserved during the evolution of various species
and might have a fundamental importance in the regulation of cell mechanisms [2–5].
3. Competing Endogenous RNAs, miRNA, lncRNA Profiling Regulation and Cancer
The miRNAs are a class of small ncRNAs that have been associated with several diseases,
including cancer [21]. They bind to target mRNAs via sequence complementarity, leading to translation
inhibition and mRNA destabilization. Several lncRNAs are capable of binding to miRNAs interfering
with this mechanism, thus blocking their action on target mRNAs. These lncRNAs are called
ceRNAs, and several examples having a role in tumorigenesis and evolution have been published.
Many lncRNA–miRNA interactions have been reported or suggested recently [22]. For example,
the lncRNA named MEG3 was recently implicated as an influencer of the signal transducer and
activator of transcription 3 (STAT3) expression, by altering miR-21 expression in ovarian cancer; it
has been shown to function as a tumor suppressor in many cancer types [23]. Maternally expressed
gene 3 (MEG3) is a maternally imprinted lncRNA with a tumor suppressor role in various tumors.
Sun et al. [24] found significantly lower MEG3 expression in endometrial carcinoma tissues than in
normal endometrial tissues.
A cross downregulation of miRNA and lncRNAs, regulating the metastasis associated lung
adenocarcinoma transcript 1 (MALAT-1) was suggested by Li et al. [25]. According to the authors,
the miR-200 family members were present in a high concentration in EEC, melanoma, and some
ovarian cancers. They showed that miR-200c levels were higher in most EEC specimens than in healthy
tissues, while MALAT-1 levels were much lower. However, they also found that miR-200c was directly
bound to MALAT-1 and miR-200c, both of which showed cross-repression, while TGF- β increased
MALAT-1 expression, working as an inhibitor of miR-200c. The interruption of the repressive effect of
miR-200c over MALAT-1 decreased the invasive capacity of EEC cells; the epithelial to mesenchymal
cell transition (EMT) markers’ expression was altered, at least in vitro [25]. However, the abnormal
expression of the lncRNA MALAT-1 or miR-200 family members were shown to facilitate EMT in
various human cancers. The details of the regulatory mechanism of MALAT1 and miR-200 remain
largely unknown.
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lncRNAs can be a precursor for miRNAs. For example, H19 is the gene precursor of a ubiquitous
lncRNAs that show a negative or limiting regulation regarding body weight and cell proliferation. H19
is the RNA precursor of miR-675 [26]. Other miRNAs have been associated with tumor progression:
Vennin et al. showed that miR-675 enhanced tumor initiation, progression, and metastasis of breast
cancer cells by downregulating the c-Cbl and Cbl-b gene coding for the CBL protein [26].
This protein is an E3 ubiquitin-protein ligase involved in cell signaling [26]. The expression
pattern and biological functions of the nuclear-enriched abundant transcript 1 (NEAT1) was also
related to EEC. The levels of NEAT1 were up-regulated in ECC tissues and cell lines [27]. Moreover,
the lncRNA cancer susceptibility candidate 2 (CASC2) was identified as a potential tumor suppressor
in EC [28].
The ovarian adenocarcinoma amplified lncRNA (OVAL) is composed of three exons of
1489 nucleotides in length. OVAL was thought to encode various expressed sequence tags (ESTs) and
mRNAs, but recently an alternative first exon isoform has been identified, leading to the transcription
of the lncRNA OVAL [29]. The OVAL is over-expressed in Type I EC and in serous ovarian cancer
(OC). Type II EC, on the other hand, is four times less likely to show upregulation of the OVAL gene;
p53-regulated genes are upregulated in EC tissue samples with high expression of OVAL [29,30].
The carcinogenetic effect of estrogens in type I EC is well-documented [31]. Endometrial cancer
and breast cancer (BC) show a similar sensitivity to estrogens. According to Bhan et al., estradiol
induces lncRNA HOTAIR expression, as well as estrogen receptors and general transcription factors
of RNA polymerase II [32]. Thus, HOTAIR is not only abnormally expressed in BC, but in EC as
well [33]. According to He et al., HOTAIR upregulation was found in nearly three-quarters of EC
samples (63 out of 87), only 20% of control endometria tested positive for this lncRNA (4 out of 30).
Moreover, differentiated tumor samples (G3 grade) showed higher expression levels than Grade 1
samples. HOTAIR gene upregulation could be detected in about 50% of hyperplastic endometriums
(5 out of 12). HOTAIR is also associated with metastatic disease. High levels of HOTAIR expression
correlates with metastases and decreased patient survival in EC [34]. The lncRNA steroid receptor
RNA activator (SRA) regulates gene expression induced by steroid receptors [35]. SRA is upregulated
in BC and in other steroid-responsive tumor tissues, such as ovarian carcinoma [36]. In EC, high levels
of SRA expression are found with no relation to histological tumor grade. In reference tissue samples
of normal endometria, SRA expression is low and this may imply an early role in tumorigenesis [35].
Curiously, according to Lanz et al., SRA-transgenic mice did not develop any tumors, even with SRA
over-expression [37].
The expression of lncRNA and their role in defining EEC subgroups and their clinical
aggressiveness must be defined further. Xu et al. suggested that six lncRNAs may be the
main regulators of endometrial carcinogenesis [38]. Xu measured a total of 172 lncRNAs and
188 mRNAs and reported that they were expressed differently in type I EC and the normal control
samples [38]. Mathematical analysis with the gene ontology (GO) pathway analysis and the
lncRNA and mRNA co-expression networks indicated that six lncRNAs (KIAA0087, RP11-501O2,
FAM212B-AS1, LOC102723552, RP11-140I24 and RP11-600K151) could be the main regulators of
endometrial carcinogenesis [38].
Another study drew a parallel between EEC and liver cancer (LC) in relation to lncRNA expression.
Jiang et al. isolated 1931 expressed lncRNAs and gave them importance as to tumor initiation with
a mathematical integrative analysis [39]. A clustering of lncRNA expression helped define three groups
according to the authors: (i) basal-like, (ii) luminal-like and (iii) Catenin, β-1 (CTNNB1)-enriched
subgroups. The basal-like subgroup had a much higher number of tumors with higher pathological
grade (p < 0.0001), and TNM stage (p = 0.01); in the luminal-like subgroup, progesterone (PGR) and
estrogen receptor (ESR1) genes were not downregulated as in the EEC basal-like subgroup. The lncRNA
profile of the CTNNB1-enriched EEC subgroup was almost equal to that of the CTNNB1-enriched LC
subgroup [39].
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Liu et al. showed that the lncRNA Taurine Upregulated Gene 1 (TUG1) was involved in EC
tumorigenesis due to the inhibition of miR-299 and miR-34a-5p [39]. The relationship between
lncRNA-TUG1 and EC was studied in 104 EC specimens, and corresponding control tissues.
lncRNA-TUG1 expression in cancer samples was higher than that in adjacent normal tissues.
The authors were able to show that lncRNA-TUG1 helps the evolution and progression of EC through
the inhibition of miR-299 and miR-34a-5p [40].
In a large study, 30,586 lncRNAs and 26,109 transcripts (fold change > 2.0) were found in 45
tested EC samples [40]. In particular, compared with normal tissues, 4010 lncRNA were upregulated,
and 3350 of them were downregulated. Among these lncRNAs, 3 were upregulated and 4 were
downregulated. Pathway analysis revealed that 24 pathways were correlated to the upregulated
transcripts [41]. Chen et al. showed that miR-93 was expressed at high levels in EC samples compared
to normal endometrial samples [42].
Zhai et al. looked into the expression profiles of lncRNAs and coding genes in three paired EC and
adjacent healthy tissues [43]. There was significant a difference in lncRNA and coding gene expression
between EC and their adjacent healthy non-tumor tissues; 53 lncRNAs (p value < 0.05) were differently
expressed in EC, compared with controls. ASLNC04080 was the most upregulated lncRNA in 22 out
of 24 samples and in HEC-1-B cell line [43]. Li et al. measured the levels of 26 lincRNAs in 176 pairs
of EC and adjacent healthy biopsy samples in two separate regional Chinese populations [44]. They
found that a lincRNA, LINC00672, was abnormally downregulated during the development of EC.
LINC00672 is a p53-targeting lincRNA, acting along with heterogeneous nuclear ribonucleoproteins as
a suppressive cofactor that reinforces p53-mediated suppression of the LIM and SH3 domain protein
(LASP)-1; this mechanism could possibly be associated with increased tumor aggressiveness [44].
Sun et al. looked into lncRNAs using support vector machine and random forest methods [45].
All expressed lncRNAs were ranked according to the standardized drop in probable prediction accuracy.
An odds analysis for predictive performance was performed, adding one lncRNA at a time starting
with the top two lncRNAs; of the ranked list, five lncRNAs were the optimal mix for diagnostic accuracy.
When choosing more than five lncRNAs, there was a downward trend in predictive performance.
The top five lncRNAs (FLJ27354, RP11-275I14.4, VIM-AS1, CTB-51J22.1 and RP11-229P13.20) were
selected as optimal predictive lncRNA biomarkers of uterine corpus EC (UCEC) progression. Only
one lncRNAs (FLJ27354) was clearly associated with disease progression, the other top four lncRNA
markers (RP11-275I14.4, VIM-AS1, CTB-51J22.1 and RP11-229P13.20) were silent. Using these top five
markers led to a high discriminatory performance in distinguishing advanced stages from early stages
with 78% prediction accuracy, 96.6% sensitivity and 76.6% specificity. These lncRNAs could have
a functional role in the progression of EC initiating, and in the promotion of important cancer-related
processes [45].
4. Regulation of Cell Growth by Long Non-Coding RNAs in Endometrioid Endometrial
Adenocarcinoma
lcnRNA H19 levels were significantly higher in EC tissues than in para-tumoral samples [45].
The expression pattern of H19 in EC tissues was addressed by quantitative polymerase chain reaction
(Q-PCR), and its function characterized in the EC cell line through the inhibition of expression with
small interfering RNAs (siRNAs) [45]. Lowering H19 levels did not affect the growth of HEC-1-B EC
cells, but it did suppress their capability to migrate and invade. Furthermore, H19 downregulation
decreased the transcription factor Snail, associated with E-cadherin downregulation, destabilization
of the adherent junction, and cellular polarization, and increased matrix metalloproteinase (MMP)
expression, with no effect on vimentin levels, indicating at least a partial reversion of EMT [46]. H19
was able to enhance EC aggressiveness by modulating the EMT process [47].
The lncRNA BANCR promotes EC cell replication and tumor invasion, by regulating Matrix
MetalloProteinase-1 (MMP1) and MMP2, and via extracellular signal-regulated kinase-1 (ERK)–MAPK
signaling pathways. BANCR was highly expressed in type 1 EC tissues, promoting EC cell proliferation,
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migration, and invasion by activating the ERK–MAPK signaling pathway that regulates MMP2 and
MMP1 expressions [48]. For this reason, BANCR could become a prognostic marker and important
drug target in type 1 EC. MEG3 and two signaling molecules, Notch1 and Hes1, were detected in
both EC tissues and cell lines by RT-PCR and western blot analysis, all of them showing significant
expression. Lentiviral vectors with whole MEG3 transcripts or Short (or small) hairpin RNA (shRNA)
targeting MEG3 (shMEG3) was transinfected to evaluate cell proliferation. MEG3 dysregulation was
studied in xenograft models (established by subcutaneous implantation), and tumor growth was
compared. Important downregulation of MEG3 was observed in EC samples compared to controls,
while levels of Notch1 and Hes1 were found to be significantly upregulated. Cell proliferation was
greatly inhibited by MEG3 over-expression, while the opposite was observed in MEG3 knockout
cells. Interestingly enough, MEG3 changes could be reversed by Notch1 regulators. Moreover,
over-expression of MEG3 was strongly associated with repressed in vivo growth, along with Notch
signaling inhibition. Downregulated MEG3 was an important anti-proliferative factor in EC, by
repressing the Notch signaling pathway [49].
Cisplatin-resistant Ishikawa cells (a human EC cell line) showed high autophagy activity
compared with non-cisplatin-resistant parent Ishikawa cells. After lncRNA profiling, HOTAIR was
identified as the culprit: it was downregulated both in cisplatin-resistant Ishikawa cells and parental
Ishikawa cells treated with cisplatin. RNA interference on HOTAIR reduced the proliferation of
cisplatin-resistant Ishikawa cells and increased autophagy in cisplatin-resistant Ishikawa cells with or
without cisplatin treatment. Furthermore, beclin-1, multidrug resistance (MDR), and P-glycoprotein
(P-gp) expression was mediated by lncRNA HOTAIR. It was concluded that HOTAIR can regulate the
cisplatin resistance of human EC cells, regulating autophagy by influencing Beclin-1, MDR, and P-gp
expression [30].
The tumor suppressor candidate 7 (TUSC7) is an antisense lncRNA: if downregulated, it acts
as a possible tumor suppressor in several cancers. In the study by Shang et al., the low expression
of TUSC7 was associated with high pathological stages of EC, which revealed that TUSC7 might be
involved in the initiation and progression of EC. Moreover, the expression of TUSC7 in EC samples
and EC cell lines resistant to cisplatin CDDP, and Taxol was lower than that in sensitive EC tissues and
cell lines, which indicated that the TUSC7 expression level was positively related to the response of EC
patients to chemotherapy with CDDP and Taxol [50].
Li et al. showed that the expression and function of NEAT1 in EEC was elevated in ECC samples
and cell lines, with a high expression levels of NEAT1 being associated with enhanced cell growth,
colony formation ability, and invasive and migratory ability in pGCMV-NEAT1, while limiting the
expression of NEAT1 in HEC-59 cells by siNEAT1 transfection showed the opposite effects [27].
Guo et al. demonstrated that the growth arrest-specific 5 (GAS5) functions as a significant tumor
suppressing lncRNA in EC. Inhibiting the expression of miR-103, GAS5 enhances the expression of
the PTEN gene leading to cancer cell apoptosis. GAS5 downregulation could represent an important
factor in the pathogenesis of EC [51].
Moreover, the lncRNA Fer-1-like protein 4 (FER1L4) might suppress EC cell proliferation.
A plasmid containing FER1L4 was transfected into HEC-50 cells, showing low levels of FER1L
expression. Western blot analysis was used to determine PTEN expression and Akt phosphorylation.
FER1L4 was significantly downregulated in EC tissues compared to controls. This was positively
correlated with decreased PTEN expression. Therefore, FER1L4 could promote PTEN expression
and inhibit Akt phosphorylation. A significant decrease of cell proliferation was observed in FER1L4
overexpressing cells, with cell cycle arrest at G0/G1 phase and enhanced apoptosis [52].
5. Long Intergenic Non-Protein Coding RNA, Regulator of Reprogramming and Endometrioid
Endometrial Adenocarcinoma
Ample evidence indicates that linc- Regulator of Reprogramming (ROR) has a significant role in
tumor initiation and progression. In tumorigenesis, linc-ROR might act as an oncogene [53]. In general,
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linc-ROR can be easily associated with cell proliferation, differentiation, apoptosis, invasion, and
metastasis in many human cancers. However, the molecules that act as mechanisms that mediate
linc-ROR’s effects must still be clearly identified before linc-ROR can be used in tumor treatment. Many
studies have shown the importance of linc-ROR as a tumor marker. Marked upregulation of linc-ROR
can be observed in various cancers, like BC [54,55], pancreatic cancer (PC) [56,57], hepatocellular
cancer (LC) [58,59], EC [60,61], and nasopharyngeal carcinoma [62]; furthermore, linc-ROR works as
a tumor suppressor in glioma [53]. Although linc-ROR is over-expressed in various cancers, the target
genes are variable and depend on the cell type.
In the paper by Chen et al., RNA was isolated from malignant and adjacent non-affected
endometrial tissue from six patients with low-grade, type I EC. Subsequently, Illumina paired-end RNA
sequencing was performed, to determine differential transcriptome expression patterns. Linc RNAs
were specifically analyzed. LINC00958 was upregulated, and four lincRNAs including LINC01480,
LINC00645, LINC00891 and LINC00702 demonstrated exquisite specificity for malignant endometrium
compared to normal endometrium, while also distinguishing EC from OC and Cervical Cancers
(CC) [62].
Zhou et al. studied a linc-RoR which was possibly implicated in the expression regulation
of core stem cell transcription factors (TFs) as ceRNA [60]. Adenovirus vectors carrying green
fluorescent protein (GFP) were transfected into E-Twenty-six (ETs) TFs to evaluate the effect of
down- or upregulation of miR-145, linc-RoR or Dicer. Expression of linc-RoR and core stem cell
TFs was associated with cell differentiation of the ET TF, whereas miR-145 expression increased
after ET differentiation. A higher expression of miR-145 successfully led to the downregulation of
linc-RoR and core TFs. The opposite was achieved by knocking down miR-145 expression. The effects
of miR-145 could be nullified by increasing the expression of linc-RoR in ETs or mutated targeted
sequences in linc-RoR. Reduced Dicer expression were able to enhance the expression of linc-RoR
and core TFs. The linc-RoR acted as a miR-145 inhibitor on the differentiation of ETs in endometrial
carcinogenesis [60].
6. Micro IRNA in Endometrioid Endometrial Adenocarcinoma
MicroRNA-93 is derived from a paralog (miR-106b-25) of the miR-17-92 cluster and has
been implicated in tumor initiation and progression of breast, colorectal, hepatic, lung, ovarian,
and pancreatic cancer.
The article by Chen et al. demonstrated miR-93 overexpression in EC tissue samples as compared
with normal endometrium. According to Chen et al., miR-93 overexpression promotes cell migration
and invasion, by downregulation of E-cadherin while N-cadherin expression in EC cells seems
significantly enhanced [42].
miRNA-205 is probably a key regulator of EC gene expression. Higher levels of miRNA-205
expression were measured in EC with invasion limited to less than half of the myometrium and
initial EC. A better survival rate was associated with higher levels of miRNA-205 using Kaplan–Maier
analysis (p = 0.034); miRNA-205 could thus be used as a prognostic marker [63]. Levels of miR-944
were analyzed in 68 cancerous and 20 normal endometrial samples: miR-944 was highly overexpressed
in EC tissues compared to normal controls. Furthermore, increased levels of miR-944 were observed
in EC cell lines. miR-944 expression was associated with the EC stages and pathology results of the
International Federation of Gynecology and Obstetrics (FIGO) [64].
Using small-RNA sequencing and microarrays, significant differences in Small Non-Coding
RNAs (sncRNA) expression patterns between normal, hyperplastic and neoplastic endometrium could
be easily identified. The authors propose a sncRNA signature (129 microRNAs, 2 of which were
previously unknown, 10 piRNAs and 3 snoRNAs) of neoplastic transformation. This new sncRNA
signature probably reflects events leading to EC development [65,66].
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Micro RNA as a Marker and Promoter of Tumor Aggression in EEC
Can miRNA evaluation accurately predict the risk of lymph node extension in EC patients?
Eighty-six matched EC cases evenly distributed between lymph node-positive and lymph
node-negative cases, were analyzed in the study by Ahsen et al. [67]. A predictive matrix was
generated using genomic miRNA expression in EC node-positive patients. An independent set of 28
other tumor samples was similarly characterized and was used in a test cohort. A predictive signature
of miRNA expression was generated and used to predict the metastatic status of the independent
test cohort. Using 18 miRNAs, 100% accuracy was obtained with the control group. The EC group
showed 90% accuracy in the node-positive cases, and 80% in node-negative cases (false discovery rate,
FDR = 6.25%) [67]. The Dicer1 endoribonuclease plays a critical role in miRNA biogenesis. Bahubeshi
et al. showed that Dicer1 dysfunction leads to the enrichment of tumor stemness and tumor aggression
both in vitro and in vivo [68]. Loss of Dicer1-induced abnormal expression of the miRNA let-7 family,
which comprises well-known tumor suppressors, thus regulating stemness in EC cells [68].
Hu showed that silencing nc886, a ncRNA, leads to apoptosis of human EC cells in vitro.
In addition, tests results showed higher level of nc886 in the late phase of human EC tissue, slightly
more than in the early phase of EC but always much higher than in normal endometrial tissue. nc886
inhibition led to increased protein levels of phosphorylated PKR (p-PKR) and caspase-3, NF-kB and
vascular endothelial growth factor (VEGF) were on the opposite decreased. The rate of apoptosis
in the nc886 inhibition group was increased and cell proliferation was much slower as compared to
controls [69].
The inhibition of the enhancer of zeste homolog 2 (EZH2), (a histone-lysine N-methyltransferase
enzyme), and the reactivation of tumor suppressor miRNAs might lead to a functional cancer therapy
regime strategy. Ihira et al. observed that EZH2-suppressed miRNA let 7b and miR-361, two possible
tumor suppressors, with consequent EC cell proliferation and invasion, and negated their stem-cell-like
properties. In EC cells, EZH2 induced and worked together with the transcription factor Yin Yang
1 (YY1) to suppress miR-361, which in turn upregulated Twist, a target of miR-361. Treating EC
cells with GSK343, a targeted EZH2 inhibitor, had the same effect of a siRNA-mediated EZH2
knockdown, upregulating miR-361 and downregulating Twist expression. Combining GSK343 with
5-AZA-2’-deoxycytidine suppressed cell proliferation with an apparent synergic effect and blocked
invasion in vitro, lowering the tumor size and weight in EC cell grafted mice. Worse patient outcomes
could be predicted: a quantitative real-time PCR (Q-RT-PCR) analysis of 24 primary EC tissues showed
that lower let-7b and miR-361 levels were dire prognostic indicators. Results were confirmed on a large
patient data set from The Cancer Genome Atlas [70]. EZH2 might drive EC progression by regulating
miR-361–Twist signaling and indicate EZH2 inhibition as a possible anti-EC therapeutic strategy [68].
miRNA-93 overexpression increased cell migration and invasion, and downregulated E-cadherin
expression while increasing N-cadherin expression [42]. Chen et al. showed, by dual-luciferase reporter
assay, that miR-93 directly binds to t 30 untranslated region of Forkhead Box A1 (FOXA1), and that its
over-expression downregulated FOXA1 expression. On the other hand, miR-93 inhibitor transfection
upregulated FOXA1 expression at protein and mRNA levels. The conclusion was that miR-93 may
aid or initiate the process of EMT in EC cells by targeting FOXA1 [42]. An intriguing hypothesis by
Gong et al. was that the miRNA-194 downregulation (miRNA-194, is an inhibitor of EMT in several
cancers) is associated to a worse prognosis in human EC. Self-renewal factor Sox3 induces EMT at
gastrulation and is also involved in EMT in several cancers. Ectopic expression of microRNA-194 in EC
stem cells induced a MET by normalizing E-cadherin expression, decreasing vimentin expression, and
interfering with cell invasion in vitro. Moreover, overexpression of microRNA-194 inhibited EC stem
cell invasion or metastasis in vivo by the injection of adenovirus microRNA-194. This demonstrates
the new mechanism by which Sox3 contributes to EC stem cell invasion and suggests that repression
of Sox3 by miRNA-194 may have a therapeutic use in the suppression of EC metastasis. The cancer
stem cell marker CD133 might be the most significant surface marker of EC stem cell [69]. The effects
of miR-29b regulate via MAPK–ERK and PI3K–Akt signaling pathways the angiogenesis in EC by
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targeting Vascular endothelial growth factor A (VEGFA). In the paper by Chen et al., EC tissues were
compared with the adjacent normal tissues and showed that miR-29b expression was downregulated,
while the mRNA and protein expression of VEGFA, ERK, Akt, mTOR and B-cell lymphoma 2 (Bcl-2)
were upregulated [71]. The left-right determination factor 2 (LEFTY2), considered a suppressor of
cell proliferation, tumor growth, and regulator of stem cell properties and embryonic differentiation,
seems to be a negative regulator of cancer cell programming.
LEFTY2 seems to downregulate MKi67 expression and focal adhesion kinase (FAK) activity, while
upregulating miR-200 and E-cadherin. It is thus a significant negative regulator of endometrial cell
growth and migration, probably under-expressed in EEC [72].
7. Conclusions
Abnormal expression of several sets of genes is probably the prime mover or a significant factor
in the progression of a cancer, and both mechanisms can be at work in sequence. Genetic alterations
include both mutational and epigenetic changes, such as methylation, acetylation, and phosphorylation
of nuclear chromatin [73–75]. Cellular genes are in charge of proliferation, apoptosis, and stem cell
differentiation; all of them can undergo epigenetic modifications in cancer [76,77]. The significance of
ncRNA is starting to be put under investigation, but more questions than answers are available for
now. Is ncRNA a possible marker of cancer risk? Can it be used as a biomarker for tumor diagnosis
and as an indicator of tumor progression or of a risk of tumor metastases? Can selective activation
or inhibition of RNA pathways help cure or control the aggressiveness of the disease? Are results
valid for all cancers? Do some of the promising preliminary results obtained in other conditions
apply to EC? Various information-carrying genes have shown important biological and regulatory
functions without expressing a translation of their information, such as classically the production of
proteins. In particular, lncRNAs show specific and altered expression patterns in EC compared to
normal endometrial tissue (Table 1, Figure 1). Some well-known factors associated with EEC show
an association with ncRNA expression. Levels of sex hormones are involved in the development of
EC. Hormones affect RNAs like lncRNAs SRA, H19 and HOTAIR, and their levels could play a role
in the carcinogenesis of EC. Estradiol is an important link between expression of these lncRNAs as it
correlates positively with upregulation of H19 and HOTAIR in EC [32,78]. Preliminary in vitro studies
showing the reduced growth of EEC cells indicate that a possible new therapeutic pathway for EEC is
possible. Study of the mechanisms of expression of RNA in EEC should be pursued, and their effect
on cancer growth clarified. lncRNAs could be useful clinical biomarkers of EEC for progression to
advanced stages. Hence, lncRNAs could be optimal biomarkers, useful to identify patients at high
risk for progression to advanced stage, and the profiling of lncRNAs could actually offer improved
diagnostic accuracy.
Figure 1. Differentially expressed long non-coding RNA (lncRNA), long intergenic non-coding RNAs
(lincRNAs) lincRNA and micro RNAs (miRNA) in Endometrial Cancer (EC).
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Table 1. Non-coding RNA expression and EC.
NcRNA Type of ncRNARegulation/Interaction
Type of EC Regulation/Pathway
Interaction
In Vivo or In Vitro Assay or
Humans Reference
LncRNA OVAL down and upregulation downregulation in type II EC andupregulation in type I EC In vitro assay from EC tissue [6]
LncRNA MALAT-1 downregulation/interactionwith miR-200 downregulation in EC through miR-200
In vitro assay from EC tissue,
xenograft tumor model [25]
LncRNA TUG1 interaction withmiR-299/miR-34a-5p
promotion of EC via miR-299 and
miR-34a-5p inhibition
In vivo mouse assay, in vitro
assay from EC tissue and
HEC-1-A cell lines
[40]
LncRNAs HOTAIR upregulation
downregulation in Cisplatin-Resistant
Ishikawa Cells (CRIC) and parental IC
treated with cisplatin; up-regulation with EC
tumor grade increase
In vitro assay CRIC cells;
in vitro assay from EC tissue [30,34]
LncRNAs H19 upregulation
upregulation with EC tumor grade increase
and other features associated with
poor prognosis
In vitro assay from EC tissues
and EC cell line [46]
LncRNAs SRA upregulation upregulation regardless of histologicaltumor grade In vitro assay from EC tissues [36]
LncRNA BANCR upregulation
promotion of EE cell proliferation and
invasion by MMP2 and MMP1 regulation via
ERK–MAPK signaling pathway in type 1 EC
In vitro assay from EC tissues [48]
LncRNAs panel (e.g., KIAA0087,
RP11-501O2, FAM212B-AS1, LOC102723552,
RP11-140I24 and RP11-600K151)
differential
regulation/interaction with 188
mRNAs
differential expression in type I EC In vitro assay from EC tissues [38]
LncRNA CASC2 downregulation potential role as a tumor suppressor In vitro assay from EC tissues [29]
LncRNA ASLNC04080 upregulation upregulation in 22–24 EC tissues andHEC-1-B cell line
In vitro assay from EC tissues
and EC cell line [43]
LncRNAs panel (e.g., FLJ27354,
RP11-275I14.4, VIM-AS1, CTB-51J22.1 and
RP11-229P13.20)
up and downregulation potential biomarkers of Uterine Corpus(UCEC) In vitro assay from EC tissues [45]
LncRNA TUSC7 downregulation related to EC tumorigenesis and progression In vitro assay from EC tissues [50]
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Table 1. Cont.
NcRNA Type of ncRNARegulation/Interaction
Type of EC Regulation/Pathway
Interaction
In Vivo or In Vitro Assay or
Humans Reference
LncRNA FER1L4 downregulation decrease of cell proliferation inFER1L4-overexpressing cells In vitro assay from EC cell line [52]
LncRNA NEAT upregulation increase of Nuclear Enriched AbundantTranscript 1 (NEAT1) in EC
In vitro assay from EC tissues
and cell lines [27]
LncRNA MEG3 downregulation anti-proliferative role in EC by repressingNotch signaling pathway
In vitro assay from EC tissues
and cell lines [49]
LncRNA GAS5/miR-103 downregulation / inhibition ofmiRNA-103 expression tumor suppressor
In vitro assay from EC tissues
and cell lines [51]
LincRNA LINC00958 upregulation increase of LINC00958 in EC In vitro assay from EC tissues [62]
LincRNA LINC00672 downregulation downregulation during EC development In vitro assay from EC tissues [44]
NcRNA Nc886 upregulation
upregulation of nc886 in EC late phases,
compared to early stages and Normal
Endometrial Tissues (NET)
In vitro assay from EC tissues [68]
miRNA-93 upregulation over-expression associated to cell migrationand invasion
In vitro assay from EC tissues
and cell lines [42]
miRNA-205 upregulation prognostic marker associated with betteroverall survival In vitro assay from EC tissues [63]
miRNA-944 upregulation over-expression in EC tissues comparedto NET In vitro assay from EC tissues [65]
miRNA-29b miRNA-29b/MAPK/ERK andPI3K/Akt signaling pathways
inhibition of angiogenesis by targeting
VEGFA through MAPK/ERK and
PI3K/Akt signaling
In vitro assay from EC tissues
and cell lines [73]
miRNA-145 upregulation upregulation of miR-145 lead todownregulation of linc-RoR7Dicer In vitro assay from EC tissues [60]
miRNA-361 miR-361/twist signaling andmiR-361/let-7b downregulation
lower let-7b, twist signaling and miR-361 are
associated with worse patient outcome In vitro assay from EC tissues [71]
miRNA-194 downregulation downregulation associated to ECpoor prognosis
In vitro assay from EC tissues
and cell lines [73]
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